Today, the VP, Controller and PAO of Ultragenyx (NASDAQ: RARE), Theodore Alan Huizenga, sold shares of RARE for $103K.
Following Theodore Alan Huizenga’s last RARE Sell transaction on May 26, 2017, the stock climbed by 22.4%.
See today’s analyst top recommended stocks >>
Based on Ultragenyx’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $10.68 million and quarterly net profit of $30.25 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $68.29 million. Currently, Ultragenyx has an average volume of 528.7K.
One of the top 25 analysts, according to TipRanks.com, recently recommended Buy RARE. Based on 10 analyst ratings, the analyst consensus is Strong Buy with an average price target of $71.89, reflecting a 8.6% upside.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.
